Virus Or Component Thereof Patents (Class 424/204.1)
  • Patent number: 10968464
    Abstract: Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 6, 2021
    Assignee: Purdue Research Foundation
    Inventor: Suresh Kumar Mittal
  • Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Patent number: 10946088
    Abstract: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 16, 2021
    Assignee: Seqirus UK Limited
    Inventors: Christoph Haussmann, Frank Hauschild, Bjorn Jobst
  • Patent number: 10940194
    Abstract: Provided are a mutated HPV58 L1 protein or a variant thereof, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein or a variant thereof and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types, and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 9, 2021
    Assignees: Xiamen University, Xiamen Innovax Biotech Co., Ltd.
    Inventors: Shaowei Li, Zhihai Li, Shuo Song, Maozhou He, Ying Gu, Ningshao Xia
  • Patent number: 10918845
    Abstract: A transdermal administration device including a first administration member including a first substrate and a first projection protruding from a first administration surface of the first substrate, and a second administration member including a second substrate and a second projection protruding from a second administration surface of the second substrate. The first substrate has an aperture, and the second substrate is positioned within the aperture when viewed in a direction perpendicular to the second administration surface.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: February 16, 2021
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventors: Hiroyuki Kato, Ichiro Takase
  • Patent number: 10920288
    Abstract: The present invention relates to methods and kits for detecting in a sample the presence of a virus particle or a virus-like particle that has reverse transcriptase activity and methods for preparing a retroviral contaminant-free substance. An aspect of the present invention is a method for detecting the presence of a virus particle in a sample of a Virus-like Particle (VLP) drug substance comprising a step of performing PCR-based reverse transcriptase (PBRT) on a sample of the VLP drug substance that has been treated with a protease.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 16, 2021
    Assignee: Takeda Vaccines, Inc.
    Inventors: Joel R. Haynes, Evelyn Benson
  • Patent number: 10912825
    Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: February 9, 2021
    Assignee: KJ Biosciences LLC
    Inventors: Yawei Ni, Jianhua Guo
  • Patent number: 10865389
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: December 15, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10858626
    Abstract: The present invention provides methods for producing and/or expanding tumor-infiltrating lymphocytes (TILs) that can be used in adoptive immunotherapy in cancer treatment.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: December 8, 2020
    Assignee: UNIVERSITÉ DE LAUSANNE
    Inventors: Marie-Agnes Doucey, Nicolas Guex, Isaac Crespo, Ioannis Xenarios
  • Patent number: 10858633
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10858634
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: December 8, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10821173
    Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: November 3, 2020
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: James J. Mond, Clifford M. Snapper, Xinle Cui
  • Patent number: 10821101
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: November 3, 2020
    Assignee: AVIXGEN INC.
    Inventors: Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek
  • Patent number: 10792354
    Abstract: An oral vaccine composition for fish, and related oral vaccine delivery system and methods for making and using such oral vaccine composition and delivery system are described. The oral vaccine composition includes virus-like particles effective to mediate an immunoprotective response in a target fish species, wherein the virus-like particles are contained in biomass of an organism or cell culture in which the virus-like particles have been expressed, optionally further including (i) adjuvant effective to enhance the immunoprotective response of the virus-like particles in the target fish species; (ii) encapsulant protectively associated with the virus-like particles for selective locus bioavailability in the target fish species; and/or (iii) binding agent aggregating the ingredients of the composition with one another.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: October 6, 2020
    Assignees: UNIVERSITY OF MARYLAND BALTIMORE COUNTY, ALLOTROPIC TECH, LLC
    Inventors: Vikram N. Vakharia, Robert Balcerzak
  • Patent number: 10772947
    Abstract: The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 15, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ramesh V. Chintala, Akhilesh Bhambhani
  • Patent number: 10738088
    Abstract: A non-naturally occurring porcine reproductive and respiratory syndrome virus (PRRSV) is provided herein, and methods of making and using the non-naturally occurring PRRSV also are provided.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 11, 2020
    Assignees: NUtech Ventures, The Board of Trustees of the University of Illinois
    Inventors: Hiep Lai Xuan Vu, Fernando Osorio, William W. Laegreid, Asit K. Pattnaik, Fangrui Ma
  • Patent number: 10731116
    Abstract: The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: August 4, 2020
    Assignee: Deuteria Beverages, LLC
    Inventors: Anthony W. Czarnik, Jeffrey A. McKinney
  • Patent number: 10702603
    Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 7, 2020
    Assignee: Biogen MA Inc.
    Inventors: Lynn Edward Conley, Yinying Tao
  • Patent number: 10668279
    Abstract: The disclosure is directed to a device for electroporating and delivering one or more antigens and a method of electroporating and delivering one or more antigens to cells of epidermal tissues using the device. The device comprises a housing, a plurality of electrode arrays projecting from the housing, each electrode array including at least one electrode, a pulse generator electrically coupled to the electrodes, a programmable microcontroller electrically coupled to the pulse generator, and an electrical power source coupled to the pulse generator and the microcontroller. The electrode arrays define spatially separate sites.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 2, 2020
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Kate Broderick, Jay McCoy, Stephen V. Kemmerrer
  • Patent number: 10668059
    Abstract: Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: June 2, 2020
    Assignee: Duke University
    Inventors: Soman N. Abraham, Ashley L. St. John
  • Patent number: 10660952
    Abstract: The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 26, 2020
    Inventors: Troy James Kaiser, Jeremy Kroll, Eric Martin Vaughn
  • Patent number: 10654899
    Abstract: The present invention relates to a protein comprising a truncated version of the HSV-2 protein mg G-2, said protein comprising: (i) an extracellular region of mg G-2 (EX-mg G-2), or a truncated version thereof, of at least 285 amino acids; said extracellular region or truncated version thereof having at least 90%, 95%, 96%, 97%, 98% or 99% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 3; (ii) a truncated transmembrane region of mg G-2 (t-TMR-mg G-2) of 2 to 15 amino acids; said truncated transmembrane region having at least 90% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 6; and (iii) an intracellular region of mg G-2 (IC-mg G-2), or a truncated version thereof, of at least 18 amino acids; said intracellular region or truncated version thereof having at least 90% or 95% sequence identity (% SI) to a peptide fragment of the corresponding length present in SEQ ID NO: 8.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 19, 2020
    Assignee: SIMPLEXIA AB
    Inventor: Jan-Åke Liljeqvist
  • Patent number: 10620204
    Abstract: The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the immunodetection methods described above.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 14, 2020
    Assignees: VANDERBILT UNIVERSITY, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James E. Crowe, Jr., Andrew I. Flyak, Alexander Bukreyev, Philipp Ilinykh
  • Patent number: 10583189
    Abstract: The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2020
    Assignee: Investigacion Aplicada, S.A. DE C.V.
    Inventors: Eduardo Lucio Decanini, José Andrés Morales Garzon
  • Patent number: 10576142
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: March 3, 2020
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10568955
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: February 25, 2020
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 10548915
    Abstract: The present invention is related to a combination for treating an EV71 infection, which comprises two or more compounds at each's non-effective level and provides an unexpected synergistic activity against EV71 replication, wherein the compound is selected from the group consisting of auranofin, ouabain, emetine, niclosamide, and S-(+)-fluoxetine.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 4, 2020
    Assignee: SUN JET BIOTECHNOLOGY INC.
    Inventors: Yeou Guang Tsay, Szu-Hao Kung
  • Patent number: 10526376
    Abstract: The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: January 7, 2020
    Assignee: University of Copenhagen
    Inventors: Adam Frederik Sander Bertelsen, Ali Salanti, Thor Theander, Susan Thrane, Christoph Mikkel Janitzek, Mette Ørskov Agerbaek, Morten Agertoug Nielsen, Jan Tobias Gustafsson
  • Patent number: 10500268
    Abstract: Disclosed are compositions and methods for related to mutant influenza viruses with increased fidelity.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: December 10, 2019
    Assignee: University of Rochester
    Inventors: Andrew Cox, Stephen Dewhurst
  • Patent number: 10472647
    Abstract: Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: November 12, 2019
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Suzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
  • Patent number: 10443040
    Abstract: Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic T-cells by using B cells treated with biological response modifier; and a use thereof. The cytotoxic T-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 15, 2019
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Hyoung Jin Kang, Sun Ok Yun, Chang-Yuil Kang
  • Patent number: 10435712
    Abstract: The present invention relates to the discovery of a high titer hybrid-virus vector that gives rise to high titer virus like vesicles (VLVs) that can be used as a vaccine. The invention includes compositions and methods of generating an evolved hybrid-virus vector vaccine and selecting high titer VLVs, methods of treating and/or preventing or immunizing against, a specific disease or disorder, and methods of inducing a memory T cell and B cell immune response in a subject administered the VLV composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a subject as well as a high titer protein expression system.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: October 8, 2019
    Assignee: Yale University
    Inventors: John Rose, Nina Rose
  • Patent number: 10426828
    Abstract: Pharmaceutical suspensions of multimeric-multiepitope influenza polypeptides, processes for their production and their use as immunizing subjects against influenza. In particular, stable aqueous microparticulate suspensions of a multimeric multiepitope polypeptide are disclosed.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 1, 2019
    Assignee: BIONDVAX PHARMACEUTICALS LTD.
    Inventors: Ram Uritski, Barry Cohen, Zohar Gadri, Shimon Hassin
  • Patent number: 10426829
    Abstract: Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 1, 2019
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
  • Patent number: 10421978
    Abstract: The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: September 24, 2019
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bernard Moss, Linda S. Wyatt, Patricia L. Earl
  • Patent number: 10385101
    Abstract: A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 20, 2019
    Assignee: VLP Therapeutics, LLC
    Inventors: Wataru Akahata, Ryuji Ueno
  • Patent number: 10329586
    Abstract: The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Andreas Gallei, Ramesh Koukuntla, Robert Barry Mandell, Alice Mundt, Kristina Rehmet, Eric Martin Vaughn
  • Patent number: 10279028
    Abstract: Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 7, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Renukaradhya J. Gourapura, Varun Dwivedi, Basavaraj S. Binjawadagi, Jordi Torrelles
  • Patent number: 10253294
    Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 9, 2019
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Marion Heuer, Manfred Lutz, Andreas Beilhack
  • Patent number: 10206993
    Abstract: This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a Lawsonia intracellularis antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: February 19, 2019
    Assignee: Zoetis Services LLC
    Inventors: Gregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
  • Patent number: 10174084
    Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 8, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventor: Takanori Sato
  • Patent number: 10144975
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: December 4, 2018
    Assignees: INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORT
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Patent number: 10130698
    Abstract: The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 20, 2018
    Assignee: Intervet Inc.
    Inventors: Vicky Fachinger, Melanie Sno, Maarten Hendrik Witvliet
  • Patent number: 10105440
    Abstract: In one aspect, the present disclosure provides compounds of formulae I and II. In another aspect, a compound of formula I or II is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 23, 2018
    Assignee: Variation Biotechnologies Inc.
    Inventor: Maura Ellen Campbell
  • Patent number: 10100101
    Abstract: Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: October 16, 2018
    Assignee: Ohio State Innovation Foundation
    Inventor: Daral John Jackwood
  • Patent number: 10071150
    Abstract: An immunity enhancing therapeutic vaccine includes a gene vector based on recombinant adenovirus and three elements: 1) an HPV antigen including the E6 and E7 multivalent fusion proteins of HPV types 16 and 18, 2) an immunologic adjuvant protein fused with said antigen, which protein may be a heat shock protein (HSP) of Mycobacterium tuberculosis, and 3) an immunostimulant, which may be granulocyte-macrophage colony stimulating factor (GM-CSF). The vaccine is used for the treatment of human papilloma virus infections and related diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: September 11, 2018
    Assignee: MYGT Biopharmaceutical LLC
    Inventors: Tao Bian, Juan Li, Xiao Xiao
  • Patent number: 10064924
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: September 4, 2018
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Stickel, Daniel Kowalewski, Claudia Berlin
  • Patent number: 10052375
    Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: August 21, 2018
    Assignee: Zoetics Services LLC
    Inventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
  • Patent number: 10039820
    Abstract: A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 7, 2018
    Assignee: Hawaii Biotech, Inc.
    Inventors: Beth-Ann Coller, Vidya Pai, Carolyn L. Weeks-Levy, Steven A. Ogata
  • Patent number: 10034929
    Abstract: The disclosure provides recombinant viral vectors and attenuated viruses and viral vaccines comprising a virus lacking a functional viral RNA suppressor of host RNAi.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: July 31, 2018
    Assignee: The Regents of the University of California
    Inventors: Shou-Wei Ding, Yang Li